Hanqi Zhang

Hanqi Zhang

Auto-generated profile, based on publicly available information

Hanqi Zhang

Jilin University

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
YSYantao Sun
Yantao Sun
SBShuyun Bi
Shuyun Bi
DSDaqian Song
Daqian Song
CQChunyu Qiao
Chunyu Qiao
DMDan Mu
Dan Mu
HZHanqi Zhang
Hanqi Zhang

1 September 2008 in Food Chemistry
Verified
Journal Article
Closed access
YWYutang Wang
Yutang Wang
JYJingyan You
Jingyan You
YYYong Yu
Yong Yu
CQChenling Qu
Chenling Qu
HZHuarong Zhang
Huarong Zhang
XLXuwen Li
Xuwen Li

1 August 2023 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
HZHan-Qi Zhang
Han-Qi Zhang
BCBu-Zi Cao
Bu-Zi Cao
QCQing-Tai Cao
Qing-Tai Cao
MHMarady Hun
Marady Hun
LCLin Cao
Lin Cao
MZMINGYI ZHAO
MINGYI ZHAO
Although COVID-19 vaccines are an effective public health tool to combat the global pandemic, serious adverse events, such as hemophagocytic lymphohistiocytosis (HLH), caused by them are a concern. In this systematic review, cases of HLH reported after COVID-19 vaccination have been examined to understand the relationship between the two and propose effective therapeutic strategies. Furthermore, ruxolitinib’s potential as a cytokine inhibitor and its affinity for CD25 were initially assessed through molecular docking, aiming to aid targeted HLH therapy. PubMed and Web of Science databases were searched for published individual case reports on the occurrence of HLH after the administration of any COVID-19 vaccine. A total of 17 articles (25 patients) were included in this qualitative analysis. Furthermore, molecular docking was employed to investigate the therapeutic potential of ruxolitinib for HLH after COVID-19 vaccination. The mean age of patients who developed HLH after COVID-19 vaccination was 48.1 years. Most HLH episodes occurred after the BNT162b2 mRNA COVID-19 vaccination (14/25 cases) and to an extent after the ChAdOx1 nCov‐19 vaccination (5/25 cases). Almost all affected patients received steroid and antibiotic therapy. Three patients died despite treatment because of esophagus rupture, neutropenic fever, bacteroides bacteremia, refractory shock, and encephalopathy and shock. Visual docking results of IL-2 Rα and ruxolitinib using the Discovery Studio 2019 Client software yielded a model score of 119.879. The findings highlight the importance of considering and identifying the adverse effects of vaccination and the possibility of using ruxolitinib for treating HLH after COVID-19 vaccination.

1 October 2014 in Talanta
Verified
Journal Article
Closed access
NLNa Li
Na Li
ZWZhibing Wang
Zhibing Wang
LZLiyuan Zhang
Liyuan Zhang
LNLi Nian
Li Nian
LLLei Lei
Lei Lei
AYAimin Yu
Aimin Yu

1 December 2024 in Journal of Translational Internal Medicine
Verified
Journal Article
Open access
PDF file
YZYutian Zou
Yutian Zou
HZHanqi Zhang
Hanqi Zhang
FLFeng Liu
Feng Liu
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen
HTHailin Tang
Hailin Tang
Article Intratumoral microbiota in orchestrating cancer immunotherapy response was published on December 1, 2024 in the journal Journal of Translational Internal Medicine (volume 12, issue 6).

1 October 2014 in Journal of Chromatography B
Verified
Journal Article
Closed access
ZWZhibing Wang
Zhibing Wang
RSRui Sun
Rui Sun
YWYuanpeng Wang
Yuanpeng Wang
NLNa Li
Na Li
LLLei Lei
Lei Lei
HZHanqi Zhang
Hanqi Zhang